+

WO2016028797A1 - Dispositif médical en soie pliable - Google Patents

Dispositif médical en soie pliable Download PDF

Info

Publication number
WO2016028797A1
WO2016028797A1 PCT/US2015/045716 US2015045716W WO2016028797A1 WO 2016028797 A1 WO2016028797 A1 WO 2016028797A1 US 2015045716 W US2015045716 W US 2015045716W WO 2016028797 A1 WO2016028797 A1 WO 2016028797A1
Authority
WO
WIPO (PCT)
Prior art keywords
silk
mesh
yarn
pattern
knitting
Prior art date
Application number
PCT/US2015/045716
Other languages
English (en)
Inventor
Enrico Mortarino
Jessica L. Akers
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/462,473 external-priority patent/US9308070B2/en
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Publication of WO2016028797A1 publication Critical patent/WO2016028797A1/fr

Links

Classifications

    • D—TEXTILES; PAPER
    • D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
    • D04B—KNITTING
    • D04B21/00—Warp knitting processes for the production of fabrics or articles not dependent on the use of particular machines; Fabrics or articles defined by such processes
    • D04B21/06—Patterned fabrics or articles
    • D04B21/08—Patterned fabrics or articles characterised by thread material
    • D—TEXTILES; PAPER
    • D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
    • D04B—KNITTING
    • D04B21/00—Warp knitting processes for the production of fabrics or articles not dependent on the use of particular machines; Fabrics or articles defined by such processes
    • D04B21/10—Open-work fabrics
    • D04B21/12—Open-work fabrics characterised by thread material
    • D—TEXTILES; PAPER
    • D10—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
    • D10B—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
    • D10B2509/00—Medical; Hygiene
    • D10B2509/08—Hernia repair mesh

Definitions

  • the present invention is a biodegradable (synonymously bioresorbable), biocompatible, pliable, knitted silk matrix, mesh or scaffold (the “device”) and methods for making and using the device in surgical and cosmetic procedures where soft tissue (i.e. a gland, organ, muscle, skin, ligament, tendon, cartilage, blood vessel or mesentery) support (through the load bearing function of the device) is desired, such as for example in breast reconstruction, breast augmentation, abdominal surgery, gastrointestinal surgery, hernia repair and facial surgery.
  • soft tissue i.e. a gland, organ, muscle, skin, ligament, tendon, cartilage, blood vessel or mesentery
  • the soft tissue support can be provided by the device itself (for example in conjunction with a hernia repair) or by the device being used in conjunction with another implant, for example use of the device on or around a tissue expander or a breast implant used in a breast reconstruction or a breast augmentation surgical procedure.
  • Soft tissue support surgical meshes and scaffolds are known and are usually made of a synthetic polymer such as Teflon ® , polypropylene, polyglycolic acid, polyester, or polyglactin 910.
  • Biomaterials such a tissue based or tissue derived material, for example an acellular dermal matrix ("ADM") obtained from human and animal derived dermis have also been used but do not have the mechanical integrity of high load demand applications (e.g.
  • ligaments, tendons, muscle or the appropriate biological functionality because most biomaterials either degrade too rapidly (e.g., collagen, PLA, PGA, or related copolymers) or are non-degradable (e.g., polyesters, metal), and in either case functional autologous tissue ingrowth (important to assist transfer of a load bearing function from an implanted biomaterial as the biomaterial is bioresorbed by the body) occurs very little or fails to occur.
  • a biomaterial may misdirect tissue differentiation and development (e.g. spontaneous bone formation, tumors) because it lacks biocompatibility with surrounding cells and tissue.
  • a biomaterial that fails to degrade typically is associated with chronic inflammation and such a response is detrimental to (i.e. weakens) surrounding and adjacent tissue.
  • Silk is a natural (non-synthetic) protein made of high strength fibroin fibers with mechanical properties similar to or better than many of synthetic high performance fibers. Silk is also stable at physiological temperatures in a wide range of pH, and is insoluble in most aqueous and organic solvents. As a protein, unlike the case with most if not all synthetic polymers, the degradation products (e.g. peptides, amino acids) of silk are biocompatible. Silk is non-mammalian derived and carries far less bioburden than other comparable natural biomaterials (e.g. bovine or porcine derived collagen). Silk, as the term is generally known in the art, means a filamentous fiber product secreted by an organism such as a silkworm or spider.
  • Silks can be made by certain insects such as for example Bombyx mori silkworms, and Nephilia clavipes spiders. There are many variants of natural silk. Fibroin is produced and secreted by a silkworm's two silk glands. As fibroin leaves the glands it is coated with sericin a gluelike substance. Spider silk s produced as a single filament lacking the immunogenic protein sericin. Use of both silkworm silk and spider silk (from a natural source or made recombinantly) is within the scope of the present invention. [005] Silkworm silk has been used in biomedical applications. The Bombyx mori species of silkworm produces a silk fiber (a "bave”) and uses the fiber to build its cocoon.
  • the bave as produced include two fibroin filaments or broins which are surrounded with a coating of the gummy, antigenic protein sericin.
  • Silk fibers harvested for making textiles, sutures and clothing are not sericin extracted or are sericin depleted or only to a minor extent and typically the silk remains at least 10% to 26% by weight sericin. Retaining the sericin coating protects the frail fibroin filaments from fraying during textile manufacture.
  • textile grade silk is generally made of sericin coated silk fibroin fibers.
  • Medical grade silkworm silk is used as either as virgin silk suture, where the sericin has not been removed, or as a silk suture from which the sericin has been removed and replaced with a wax or silicone coating to provide a barrier between the silk fibroin and the body tissue and cells.
  • Physicians prefer and require an implantable, knitted silk medical device with the flexibility to be stretched, expanded, pulled into shape, elongated and/or draped into place over, around or under soft tissue or an implant at the time of a soft tissue surgical or medical procedure, without the silk medical device upon its elongation breaking, splitting or unraveling.
  • an implantable, knitted silk medical device with the flexibility to be stretched, expanded, pulled into shape, elongated and/or draped into place over, around or under soft tissue or an implant at the time of a soft tissue surgical or medical procedure, without the silk medical device upon its elongation breaking, splitting or unraveling.
  • the device in one embodiment is a pliable, knitted mesh having at least two yarns laid in a knit direction and engaging each other to define a plurality of nodes, the at least two yarns including a first yarn and a second yarn extending between and forming loops about two nodes, the second yarn having a higher tension at the two nodes than the first yarn, the second yarn substantially preventing the first yarn from moving at the two nodes and substantially preventing the knitted mesh from unraveling at the nodes.
  • the device is a surgical mesh made of silk that is knitted, multi-filament, and bioengineered. It is mechanically strong, biocompatible, and long-term bioresorbable.
  • the sericin-extracted silkworm fibroin fibers of the device retain their native protein structure and have not been dissolved and/or reconstituted.
  • "Bioresorbed" means that none or fewer than 10% of the silk fibroin fibers of the device can be seen to the naked (no magnification aid) eye upon visual inspection of the site of implantation of the device or of a biopsy specimen therefrom, and/or that the device is not palpable (i.e. cannot be felt by a surgeon at a time after the surgery during which the device was implanted) upon tactile manipulation of the dermal location of the patient at which the device was implanted. Typically either or both of these bioresorbed determinants occur about 1 to about 5 years are in vivo implantation of the device.
  • the device of the present invention is a pliable, sterile surgical mesh or scaffold available in a variety of shapes and sizes ready for use in open surgical or in laparoscopic procedures.
  • the device is flexible and well-suited for delivery through a laparoscopic trocar due to its strength, tear resistance, suture retention, and ability to be cut in any direction.
  • the device can provide immediate physical and mechanical stabilization of a tissue defect through the strength and porous (scaffold-like) construction of the device.
  • the device can be used as a transitory scaffold for soft tissue support and repair to reinforce deficiencies where weakness or voids exist that require the addition of material to obtain the desired surgical outcome.
  • the device can comprise filament twisted silk yarns.
  • the silk is made of silk fibroin fibers.
  • the silk fibroin fibers are preferably sericin depleted or sericin extracted silk fibroin fibers.
  • the device has an open pore knit structure.
  • the device and ingrown native tissue can maintain at least about 90% of the time zero device strength of the device at one month or at three months or at six months in vivo after the implantation.
  • the device can be implanted without regard to side orientation of the device and the combined thickness of the device and ingrowth of native tissue scaffold increases with time in vivo in the patient.
  • fibroin includes silkworm fibroin (i.e. from Bombyx mori) and fibroin-like fibers obtained from spiders (i.e. from Nephila clavipes).
  • silk protein suitable for use in the present invention can be obtained from a solution containing a genetically engineered silk, such as from bacteria, yeast, mammalian cells, transgenic animals or transgenic plants. See, for example, WO 97/08315 and US Patent No. 5,245,012.
  • the device is a pliable, knitted silk fabric intended for implantation in a human body.
  • the word "knit” is synonymous with the word “knitted”, so that a knit silk fabric is the same as a knitted silk fabric.
  • the device can be a warp knit or can be weft knit silk fabric.
  • the device according of the present invention is a pliable, biocompatible, warp knit, multi-filament silk fabric.
  • a woven material or fabric is made by weaving, which is a process that does not use needles, and results in a fabric with different characteristics.
  • a woven fabric is made by a non-needle process using multiple yarns that interlace each other at right angles to form a structure wherein one set of yarn is parallel to the direction of fabric formation.
  • Woven fabrics are classified as to weave or structure according to the manner in which warp and weft cross each other.
  • the three main types of weaves (woven fabrics) are plain, twill, and satin.
  • Woven (weaved) silk fabric, woven textiles and woven fabrics are not within the scope of the present invention.
  • Non-woven fabrics are also not within the scope of the present invention.
  • Non-woven (also refer to as bonded) fabrics are formed by having multiple fibers cohered together chemically or physically, without use of needles.
  • a knitted fabric is generally softer and more supple because its thread is treated differently.
  • a knitted fabric is made by using needles (such as for example the needles of a single or double bed knit machine) to pull threads up through the preceding thread formed into a loop by the needle.
  • needles such as for example the needles of a single or double bed knit machine
  • the knitted fabric can have one or multiple yarn intermeshing (also referred as interloping).
  • the device is made of biodegradable silk and is a biocompatible, non-woven, knit, multi-filament silk fabric or mesh.
  • Embodiments according to aspects of the present invention provide a biocompatible surgical silk mesh device for use in soft or hard tissue repair.
  • soft tissue repair include hernia repair, rotator cuff repair, cosmetic surgery, implementation of a bladder sling, or the like.
  • hard tissue repair such as bone repair, involve reconstructive plastic surgery, ortho trauma, or the like.
  • the open structure of the device allows tissue ingrowth as the silk forming the device is bioresorbed, at a rate permitting smooth transfer of mechanical properties to the new tissue from the device.
  • the device has a knit pattern that substantially or entirely prevents unraveling, especially when the device is cut.
  • the device have a stable knit pattern made by knitting silk yarn with variations of tension between at least two yarns laid in a knit direction. For example, a first yarn and a second yarn may be laid in a knit direction to form "nodes" for a mesh device.
  • the knit direction for the at least two yarns for example, may be vertical during warp knitting or horizontal during weft knitting.
  • the nodes of a mesh device also known as intermesh loops, refer to intersections in the mesh device where the two yarns form a loop around a knitting needle.
  • the first yarn is applied to include greater slack than the second yarn, so that, when a load is applied to the mesh device, the first yarn is under a lower tension than the second device.
  • a load that places the at least two yarns under tension may result, for example, when the mesh device is sutured or if there is pulling on the mesh device.
  • the slack in the first yarn causes the first yarn to be effectively larger in diameter than the second yarn, so that the first yarn experiences greater frictional contact with the second yarn at a node and cannot move, or is "locked," relative to the second yarn. Accordingly, this particular knit design may be referred to as a "node-lock" design.
  • the device bioresorbs at a rate sufficient that allows tissue in-growth while transferring the load-bearing responsibility to the native tissue.
  • An embodiment of the device can be made from Bombyx mori silkworm silk fibroin or from spider silk.
  • the raw silk fibers have a natural globular protein coating known as sericin, which may have antigenic properties and must be depleted before implantation. Accordingly, the yarn is taken through a depletion process as described, for example, by Gregory H. Altman et al., "Silk matrix for tissue engineered anterior cruciate ligaments," Biomaterials 23 (2002), pp. 4131 -4141 , the contents of which are incorporated herein by reference.
  • the silk material used in the device embodiments contains substantially no (less than 5%) sericin.
  • a process for making the pliable, knitted silk mesh can have the steps of: knitting a first silk yarn in a first wale direction using the knit pattern 3/1 -1/1 -1/3-3/3; knitting a second silk yarn in a second wale direction using the knit pattern 1/1 -1/3-3/3-3/1 ; knitting a third silk yarn in a first course direction using the knit pattern 3/3-3/3-5/5-5/5-3/3-3/3-5/5-5-1/1 -1/1 -5/5-5/5-3/3-3/3-5/5-5/5-3/3-3/3- 7/7-7/7, and; knitting a fourth silk yarn in a second course direction using the knit pattern 1 n -5/5-5/5-3/3-3/3-5/5-5/5-3/3-3/3-7/7-7/7-3/3-3/3-5/5-5/5-3/3-3/3-5/5-5/5-1/1 , thereby obtaining the pliable knitted silk mesh.
  • the two movements in the wale direction occur on separate needle beds, with alternate yarns, and with loops formed on the course movements staggered within the repeat knit pattern.
  • the silk yarns can be made of a nine filament, twisted, and sericin depleted silk fibers, and the yarns can be made with three ends of Td 20/22 raw silk twisted together in the S direction to form a ply with 20 tpi and further combining 3 of the resulting ply with 10 tpi in the Z direction.
  • the e stitch density or pick count for silk mesh design can be about 40 picks per centimeter including the total picks count for the technical front face and the technical back face of the mesh, or equivalently about 20 picks per cm considering only one face of the mesh.
  • a detailed process for making the pliable knitted silk mesh can have the steps of: knitting a first silk yarn in a first wale direction using the pattern 3/1 - 1/1 -1/3-3/3; knitting a second silk yarn in a second wale direction using the pattern 1/1 - 1/3-3/3-3/1 ; knitting a third silk yarn in a first course direction using the pattern 3/3-3/3- 5/5-5/5-3/3-3/3-5/5-5/1/1 -1/1 -5/5-5/5-3/3-3/3-5/5-5/5-3/3-3/3-7/7-7/7, and; knitting a fourth silk yarn in a second course direction using the pattern 1/1 -5/5-5/5-3/3-3/3-5/5- 5/5-3/3-3/3-7/7-7/7-3/3-3/3-5/5-5/5-3/3-3/3-5/5-5/5-1/1 , wherein: the two movements in the wale direction occur on separate needle beds with alternate yarns and loops that occur on every course are staggered within repeat; the silk yarns are made of a nine filament, twisted, and
  • the pliable, knitted silk mesh can have percent elongation at break of between about 4% or 32% to about 109% or 1 10%, a burst strength of about 0.45 MPa, and a stiffness of about 25 N/mm.
  • a process for making a pliable, knitted silk mesh comprising the steps of: knitting a first silk yarn in a first wale direction using the knit pattern 3/1 -1/1 - 1/3-3/3; knitting a second silk yarn in a second wale direction using the knit pattern 1/1 - 1/3-3/3-3/1 , knitting a third silk yarn in a first course direction using the knit pattern 3/3- 3/3-5/5-5/5-3/3-3/3-5/5-5/5-11 ⁇ -1 / ⁇ -5/5-5/5-3/3-3/3-5/5-5/5-3/3-3/3-7/7-7/7, and; knitting a fourth silk yarn in a second course direction using the knit pattern 1/1 -5/5-5/5-3/3-3/3- 5/5-5/5-3/3-3/3-3/7/7-7/7-3/3-3/3-5/5-5/5-5-1/1 .thereby obtaining the pliable knitted silk mesh.
  • the two movements in the wale direction occur on separate needle beds (a knitting machine having two needle beds); and (b) with alternate yarns such as they knit with the opposing needle bed to their location (the front set of yarn knit with the back needle bed and the back set of yarn knit with the front needle bed).
  • the silk yarns are made of a nine filaments ("filaments" can be defined as raw silk yarn having a finesse of about Td 20/22) of twisted, and sericin depleted silk fibers.
  • the yarns are made with three ends of raw silk yarn twisted together having a finesse of Td 20/22 twisted together in the S direction (clockwise direction of twist) to form a ply with 20 tpi (twist per inch is the number of twist measured in an inch of yarn) and further combining 3 of the resulting ply with 10 tpi in the Z direction(counter clockwise direction of twist), and the stitch density or pick count for silk mesh design is about 40 picks per centimeter including the total picks count for the technical front face and the technical back face of the mesh, or equivalently about 20 picks per cm considering only one face of the mesh.
  • Our invention also includes a process for making a pliable knitted silk mesh, the process comprising the steps of: knitting a first silk yarn in a first wale direction using the pattern 3/1 -1/1 -1/3-3/3; knitting a second silk yarn in a second wale direction using the pattern 1/1 -1/3-3/3-3/1 , knitting a third silk yarn in a first course direction using the pattern 3/3-3/3-5/5-5/5-3/3-3/3-5/5-5/5-1/1 -1/1 -5/5-5/5-3/3-3/3-5/5-5/5-3/3-3/3-7/7-7/7, and; knitting a fourth silk yarn in a second course direction using the pattern 1/1 -5/5-5/5- 3/3-3/3-5/5-5/5-3/3-3/3-7/7-7/7-3/3-3/3-5/5-5/5-3/3-3/3-5/5-5/5-1/1 , wherein: (e) the two movements in the wale direction occur on separate needle beds with alternate yarns and loops that occur on every course are staggered within repeat; (f) the silk yarns are made of
  • Our invention also includes a pliable knitted silk mesh made by: knitting a first silk yarn in a first wale direction using the pattern 3/1 -1/1 -1/3-3/3; knitting a second silk yarn in a second wale direction using the pattern 1/1 -1/3-3/3-3/1 , knitting a third silk yarn in a first course direction using the pattern 3/3-3/3-5/5-5/5-3/3-3/3-5/5-5/1/1 -1/1 - 5/5-5/5-3/3-3/3-5/5-5/5-3/3-3/3-7/7-7/7, and; knitting a fourth silk yarn in a second course direction using the pattern 1/1 -5/5-5/5-3/3-3/3-5/5-5/5-3/3-3/3-7/7-7/7-3/3-3/3- 5/5-5/5-3/3-3/3-5/5-5/5-1/1 .
  • the silk yarns are made of a nine filament, twisted, and sericin depleted silk fibers, and; the yarns are made with 3 ends of Td 20/22 raw silk twisted together in the S direction to form a ply with 20 tpi and further combining 3 of the resulting ply with 10 tpi in the Z direction, and; the stitch density or pick count for silk mesh design is 40 picks per centimeter including the total picks count for the technical front face and the technical back face of the mesh, or equivalently 20 picks per cm considering only one face of the mesh.
  • Our invention also includes a pliable knitted silk mesh made by: knitting a first silk yarn in a first wale direction using the pattern 3/1 -1/1 -1/3-3/3; knitting a second silk yarn in a second wale direction using the pattern 1/1 -1/3-3/3-3/1 , knitting a third silk yarn in a first course direction using the pattern 3/3-3/3-5/5-5/5-3/3-3/3-5/5-5/1/1 -1/1 - 5/5-5/5-3/3-3/3-5/5-5/5-3/3-3/3-7/7-7/7, and; knitting a fourth silk yarn in a second course direction using the pattern 1/1 -5/5-5/5-3/3-3/3-5/5-5/5-3/3-3/3-7/7-7/7-3/3-3/3- 5/5-5/5-3/3-3/3-5/5-5/5-1/1 , wherein: (e) the two movements in the wale direction occur on separate needle beds with alternate yarns and loops that occur on every course are staggered within repeat; (f) the silk yarns are made of a nine filament, twisted, and se
  • FIG. 1A is a photograph of a pattern layout for a silk-based scaffold design in accordance with the present invention.
  • FIGS. 1 B and 1 C illustrate an example pattern layout for the scaffold design of FIG. 1A including all pattern and ground bars according to aspects of the present invention.
  • FIGS. 1 D and 1 E illustrate an example pattern layout for a double needle bed mesh or scaffold according to aspects of the present invention from FIG. 1 B for ground bar #4.
  • FIGS. 1 F and 1 G illustrate an example pattern layout for a double needle bed mesh or scaffold according to aspects of the present invention from FIG. 1 B for pattern bar #5.
  • FIGS. 1 H and 1 1 illustrate an example pattern layout for a double needle bed mesh or scaffold according to aspects of the present invention from FIG. 1 B for ground bar #7.
  • FIG. 1 J illustrates an example pattern simulation for a double needle bed mesh demonstrated in FIG. 1 B according to aspects of the present invention.
  • Fig 1 K shows the yarn feed rates used during the knit process used to make the most preferred embodiment of the device within the scope of the present invention.
  • FIG. 2 illustrates the twisting and multi-ply nature of a yarn comprised of silk fibroin bundles as used in an embodiment of the present invention.
  • FIG. 3A and 3B show respectively scanning electromicrographs ("SEM") of native silk fibers and sericin extracted silk fibers, the latter being used to make the device.
  • SEM scanning electromicrographs
  • Figure 4 is a photograph of an embodiment (a knitted silk fabric ready for implantation) of a device within the scope of the present invention (placed above a millimeter ruler).
  • Figure 5A is photograph at 16X magnification of a portion of the Figure 4 embodiment.
  • Figure 5B is photograph of the Figure 4 embodiment showing the ease with which it can be cut without the fabric unraveling or fraying.
  • Figure 6 is a photograph of a pattern layout for a silk-based scaffold design in accordance with the present invention ("the device" of Example 1 )
  • Figures 7 represent one of the element for the pattern layout making the device on a raschel knitting machine.
  • 7A is the needle layout over two needle bed (front and back);
  • 7B represent the yarn evaluation for the 4 bars making the device in Fig.6;
  • 7B is one of the grid equivalent to one needle space and one course (front or back of the pattern)
  • Figure 8 represent one of the element for the pattern layout making the device on a raschel knitting machine.
  • 8A is the threading sequence for the guide bar heddle, each color dot represent one heddle eyelet; 8B is the bar and devices numbering sequence.
  • Figure 9 represent one of the element for the pattern layout making the device on a raschel knitting machine.
  • 9A is the sequence for the movements making up the pattern bars;
  • 9B is the sequence for the value making up the take down;
  • 9C-9D-9E are the sequences for the feed rate of the yarn making up the pattern.
  • the present invention is based on discovery of an implantable, bioresorbable, biocompatible, pliable, knitted, porous silk mesh (the "device") which upon implantation provides soft tissue support and, as the device bioresorbs, transfer of its load bearing (support) function to new tissue formed at the site of implantation.
  • the device is preferably made from Bombyx mori silkworm silk. It can also be made from spider silk, including recombinantly made spider silk.
  • the preferred knit pattern of the device accomplishes variation in tension between yarns at the knit nodes (the yarn interlocking loops) thereby preventing unraveling of the mesh when cut for use in surgery.
  • Figure 5A shows a 16x magnification of the device knit pattern and
  • Figure 5B shows ease of cutting without fraying or unraveling.
  • the device made according to the present invention allows significant and consistent tissue ingrowth while bioresorbing at a rate which permits smooth transfer of load bearing support to the newly formed tissue.
  • the device is made of a biocompatible silk protein that is eventually bioresorbed.
  • the raw silk fibers obtained from Bombyx mori silkworms comprise a fibroin protein core filament coated with the antigenic globular protein sericin.
  • the sericin is removed or substantially all removed by hot aqueous (i.e. soap) extraction (wash) leaving behind fibroin protein filament consisting of layers of antiparallel beta sheets which provide both stiffness and toughness.
  • Figure 3A is a SEM photograph of native (sericin coated) silk fibers, and Figure 3B of the fibers after sericin extraction, as then used to make (knit) the device.
  • the porous knit structure of the device so made is shown by Figures 1A, 4 and 5.
  • the device provides immediate physical and mechanical stabilization of tissue defects because of its strength and porous construction and is useful as a transitory scaffold for soft tissue support and repair. It provides reinforcement for deficiencies where weakness or voids exist that require additional material reinforcement to obtain the desired surgical outcome.
  • the bioresorption process occurs over time after implantation of the device as tissue in-growth and neovascularization takes place.
  • the device can be used to assist soft tissue repair.
  • soft tissue repair include breast reconstruction, hernia repair, cosmetic surgery, implementation of a bladder sling, or the like.
  • FIG. 1 A is a photograph of a pattern layout for a device (silk-based mesh or scaffold) in accordance with the present invention.
  • FIG. 1A shows the wale direction 10 and the course direction 15 and placement of the silk yarns in either the wale 10 or course 15 scaffold material direction or location.
  • the device is preferably formed on a raschel knitting machine such as Comez DNB/EL-800-8B set up in 10 gg needle spacing by the use of three movements as shown in pattern layout in FIGS. 1 B and 1 C: two movements in the wale direction, the vertical direction within the fabric, and one movement in the course direction, the horizontal direction of the fabric.
  • the movements in the wale direction occur on separate needle beds with alternate yarns; loops that occur on every course are staggered within repeat.
  • the yarn follows a repeat pattern of 3/1 -1/1 -1/3-3/3 for one of the wale direction movements as shown in FIGS. 1 D and 1 E and 1/1 -1/3-3/3-3/1 for the other wale direction movement as shown in FIGS. 1 H and 1 1.
  • the interlacing of the loops within the fabric allows for one yarn to become under more tension than the other under stress, locking it around the less tensioned yarn, thereby keeping the fabric from unraveling when cut.
  • the other movement in the course direction as shown in FIG. 1 F and 1 G occurs in every few courses creating the porous design of the device.
  • These yarns follow a repeat pattern of 7/7-9/9-7/7-9/9-7/7-9/9/-1/1 - 1/1 -3/3-1/1 -3/3-1/1 -3/3-1/1 -3/3-1/1 -3/3-1/1 for the course direction movement.
  • the pattern simulation layout of this pattern was rendered using ComezDraw 3 software in FIG.
  • FIGS. 1 B to 1 1 are the optimum values for the specific yarn design used for the pattern simulation layout of FIG. 1 J.
  • FIG 1 J item 17 is a simulated double needle bed mesh or scaffold.
  • Fig 1 F following standard terminology well known in the knit industry "F” means front and "B” means back and with regard to Fig 1 F shows the incremental sequence of pattern lines for the course direction.
  • the numbers “12, 9, 6 and 3" at the bottom of Fig 1 F represent the number of needles in the needle bed starting count from left to right.
  • the upwards pointing arrows near the bottom of Fig 1 F show the needle slots occupied by a needle actively engaged with the yarn for the knit machine/knit process.
  • Rows 1 F to 6B of Fig 1 F show the knit pattern used to make the device.
  • the Fig 1 F rows 1 F to 6B knit pattern is repeated 94 times to make a 25 cm sheet length of the fabric of the device, the number of repeats of the pattern being fewer or more if respectively a smaller or larger section of device fabric is desired to result from the knit process.
  • the Fig 1 F rows 1 F to 6B knit pattern is equivalently described by the above set forth, combined three knit movement: the first wale direction 3/1 -1/1 -1/3-3/3 knit pattern; the second wale direction 1/1 -1/3-3/3-3/1 knit pattern, and; the course direction 7/7-9/9-7/7-9/9-7/7-9/9/-1/1 -1/1 -3/3-1/1 -3/3-1/1 knit pattern.
  • Rows 7F to 10B in Fig 1 F show the knit pattern used to make a spacer which creates a kitted area of fabric separation (i.e. a cut location) between adjacent 25 cm lengths of the knitted device fabric which is knitted by the process set forth above as one continuous sheet of fabric.
  • the specific feed rates for the yarn forming this most preferred embodiment of the device is shown in Fig 1 K where column 17 shows the yarn feed rate used for the first wale direction 3/1 -1/1 -1/3-3/3 knit pattern.
  • a rate of 212 is equivalent to 74.8 cm of yarn per 480 coursed or per rack.
  • Fig 1 K reports the yarn feed rate that is used for the second wale direction 1/1 -1/3-3/3-3/1 knit pattern, where again a rate of 212 is equivalent to 74.8 cm of yarn per 480 coursed or per rack.
  • Column 22 of Fig 1 K shows the yarn feed rate that is used for the course direction 7/7-9/9-7/7-9/9-7/7-9/9/- 1/1 -1/1 -3/3-1/1 -3/3-1/1 -3/3-1/1 -3/3-1/1 -3/3-1/1 -3/3-1/1 -3/3-1/1 knit pattern; a rate from line 1 F to 6B of 190 is equivalent to 67.0 cm of yarn per 480 coursed or per rack, while a rate from line 7F to 10B of 90 is equivalent to 31 .7 cm of yarn per 480 coursed or per rack.
  • the knit pattern shown in FIG. 1A can be knit to any width depending upon the knitting machine and can be knitted with any of the gauges available with the various crochet machines or warp knitting machines.
  • Table 1 outlines the device fabric widths that may be achieved using a different numbers of needles on different gauge machines. The dimensions in Table 1 are approximate due to the shrink factor of the knitted fabric which depends on stitch design, stitch density, and yarn size used.
  • the device was knit with 9-filament, twisted silk yarns.
  • a yarn was made from three silk bundles, each of which was comprised of individual silk fibrils as illustrated in FIG. 2.
  • the 9-filament yarns were knit into the surgical scaffold.
  • the wales ran horizontally and the courses ran vertically along the scaffold.
  • a preferred embodiment of the device ready for surgical use has a thickness between about 0.6 mm and about 1 .0 mm, a width of about 10 cm ( ⁇ about 1 cm) and a length of about 25 cm ( ⁇ about 3 cm).
  • the device has pores with an average diameter greater than about 10,000 urn 2 , a density of from about 0.14 mg/mm 3 to about 0.18 mg/mm 3 (as determined by dividing the mass of the device by its volume [thickness, width, and length multiplied together]), and is comprised of at least about 95% silk fibroin.
  • the device has a burst strength of from about 0.54 MPa to about 1 .27 MPa, and a stiffness of between about 30N/mm to about 50 N.mm (the latter two mechanical properties of the preferred device determined by American Society for Testing and Materials D3787-07, "Standard Method for Burst Strength of Textiles: Constant Rate of Transverse Ball Burst Test” or ASTM F2150-07 Standard Guide for Characterization and Testing of Biomaterial Scaffolds Used in Tissue Engineered Medical Products)
  • the cross-sectional area of full pores of the scaffold was measured using a microscope with sufficient magnification and image capture capability. The magnification was selected based upon the resolution of the pores in the knit pattern being examined.
  • Burst stiffness was calculated by determining the slope of the middle 60% of the linear region of the compressive load vs. extension curve.
  • the exposed area was the circular area of the test article covering the radius (r) of the inner fixture diameter and was calculated using the equation below.
  • the device was loaded by clamping the first 10 mm of the sample into the upper clamp and allowing the remainder of the sample to fall unrestrained into the bottom clamp opening. The last 10 mm of the sample was held by the bottom clamp. Care was taken to avoid pre-staining the device sample.
  • the actuator height was adjusted so that the sample had a pre-load of 2N.
  • the actuator position was adjusted to achieve a specific gauge length and then reset to the zero- position at this point.
  • the device sample was strained until it experienced ultimate tensile failure. The average maximum tensile strength, maximum tensile stress, percent elongation at break, and the tensile stiffness were determined. Tensile stiffness was calculated by determining the slope of the trend line of the linear portion of the tensile load vs. elongation curve bound by an upper and lower tensile load.
  • Tensile stiffness was calculated as the slope of the linear portion of the load verses elongation curve. The average maximum tensile strength, maximum tensile stress, linear stiffness, and percent elongation at break were determined.
  • the thickness and width were provided by the respective device sample thickness and width measurements.
  • the height of the mechanical equipment crosshead was adjusted so that the actuator was positioned to allow for a defined amount of upward movement and a specific sample gauge length resided between the upper and lower clamps.
  • the device sample was placed in the upper clamp. The top 10 mm of the sample was covered by the clamp. The device sample was positioned so that the cut was located on the left side. The sample was aligned perpendicular with the clamp before the clamp was closed. The bottom portion of the sample was allowed to fall unrestrained into the bottom clamp opening. The clamp was closed and the sample was preloaded with 3N. The sample was strained at a constant rate until the sample tore at the cut point. From the resulting data the maximum tear resistance load was obtained.
  • Embodiments of the device according to the present invention can be knitted on a fine gauge crochet knitting machine.
  • a non-limiting list of crochet machines capable of manufacturing the surgical mesh according to aspects of the present invention are provided by: Changde Textile Machinery Co., Ltd.; Comez; China Textile Machinery Co., Ltd.; Huibang Machine; Jakkob Muller AG; Jingwei Textile Machinery Co., Ltd.; Zhejiang Jingyi Textile Machinery Co., Ltd.; Dongguan Kyang Yhe Delicate Machine Co., Ltd.; Karl Mayer; S rotating Machine; Sino Techfull; Suzhou Huilong Textile Machinary Co., Ltd.; Taiwan Giu Chun Ind. Co., Ltd.; Zhangjiagang Victor Textile; Liba; Lucas; Muller Frick; and Texma.
  • Embodiments of the device according to the present invention can be knitted on a fine gauge warp knitting machine.
  • warp knitting machines capable of manufacturing the surgical mesh according to aspects of the present invention are provided by: Comez; Diba; Jingwei Textile Machinery; Liba; Lucas; Karl Mayer; Muller Frick; Runyuan Warp Knitting; Taiwan Giu Chun Ind.; Fujian Xingang Textile Machinery; and Yuejian Group.
  • Embodiments of the device according to the present invention can be knitted on a fine gauge flat bed knitting machine.
  • a non-limiting list of flat bed machines capable of manufacturing the surgical mesh according to aspects of the present invention are provided by: Around Star; Boosan; Cixing Textile Machine; Fengshen; Flying Tiger Machinary; Fujian Hongqi; G & P; Gorteks; Jinlong; JP; Jy Leh; Kauo Heng Co., Ltd.; Matsuya; Nan Sing Machinery Limited; Nantong Sansi Instrument; Shima Seiki; Nantong Tianyuan; and Ningbo Yuren Knitting.
  • a test method was developed to check the cutability of the device formed according to aspects of the present invention.
  • the device evaluated according to the number of scissor strokes needed to cut the device with surgical scissors. The mesh was found to cut excellently because it took only one scissor stroke to cut through it.
  • the device was also cut diagonally and in circular patterns determining that the device did not unraveled once cut in either or both its length and width directions (see Figure 5B). To determine further if the device would unravel a suture was passed through the closest pore from the cut edge, and pulled. This manipulation did not unravel the device. Thus the device was easy to cut and did not unravel after manipulation.
  • a device according to the present invention has been found to bioresorb by 50% in approximately 100 days after implantation, that is at least about 50% of the mass of the device bioresorbs after about 100 days after implantation in a human patient.
  • Physical properties of the device include thickness, density and pore sizes.
  • the thickness of the device was measured utilizing a J100 Kafer Dial Thickness Gauge.
  • a Mitutoyo Digimatic Caliper was used to find the length and width of the samples; used to calculate the density of the device.
  • the density was found by multiplying the length, width and thickness of the mesh then dividing the resulting value by the mass.
  • the pore size of the device was found by photographing the mesh with an Olympus SZX7 Dissection Microscope under 0.8x magnification. The measurements were taken using ImagePro 5.1 software and the values were averaged over several measurements. Physical characteristics of sample meshes, and two embodiments of the device are shown in Table 2. Table 2
  • the device in Examples 1 -6) and methods for making the device.
  • pliable it is meant that the device can stretched to increase its length and/or its width by between about 4% to about 1 10% before breaking (see Table 5 below).
  • the device is a pliable, knitted, biocompatible silk scaffold device that can be implanted in a surgical procedure to provide soft tissue repair and soft tissue support, including to support an implant such as a breast implant or a tissue expander. Examples of soft tissue repair surgical procedures include breast reconstruction, hernia repair, cosmetic surgery, and implementation of a bladder sling.
  • the device can employ a variety of polymer materials, preferable the device is made of silk, such as Bombyx Mori silkworm silk fibroin.
  • the raw silk fibers used to make the device have a natural globular protein coating known as sericin, which may have antigenic properties and must be depleted before implantation of the device. Accordingly, yarn used to make the device is taken through a sericin depletion process as described in Altman et al., "Silk matrix for tissue engineered anterior cruciate ligaments," Biomaterials 23 (2002), pp. 4131 -4141 , the contents of which are incorporated herein by reference in its entirety. After the depletion process the silk material used in the device embodiments contains substantially no sensitizing agents.
  • the device is preferably made by knitting sericin depleted silk yarn to form a porous mesh or fabric.
  • the knitting can be carried out as raschel knitting, warp knitting and weft knitting.
  • the fabric of the device can be treated to enhance one or more device characteristics.
  • the device treatment can be a finishing or surface coating process which can increase device hydrophilicity, biocompatibility and mechanical properties, such as handling for ease of cutting and graft pull-through, as well as add an anti-microbial or anti-fungal coatings.
  • Specific examples of device surface treatments can include:
  • protein such as but not limited to fibronectin, denatured collagen or gelatin, collagen gels and
  • peptides contain one silk-binding sequence and one biologically active ⁇
  • Embodiments of a prosthetic device according to our invention can be knitted on a fine gauge warp knitting machine.
  • warp knitting machines capable of manufacturing the device: Comez; Diba; Jingwei Textile Machinery; Liba; Lucas; Karl Mayer; Muller Frick; Runyuan Warp Knitting; Taiwan Giu Chun Ind.; Fujian Xingang Textile Machinery; and Yuejian Group.
  • Embodiments of the device were knitted on a COMEZ DNB/EL-800-8B/P - 20 warp knitting machine in 20 gauge with stroke for each of the positions from 1 through 30 as shown in Table 4.
  • Table 4
  • Our device has defornnation properties that can be controlled by varying parameters within the device design, as set forth below to achieve desired device deformation (“i.e. pliable") properties.
  • a preferred and desired deformation property is the ability of the knitted device to exhibit at least about a 30-35% extension of its length in the machine direction and at least about 25-30% extension of its length in the cross direction without breaking or unraveling. These device properties are desired because they provide stretch or pliability for the physician user at the time of device implantation, therefor permitting the user to alter the device dimensions at the time of device implantation.
  • FIG. 6 is a photograph of an embodiment of a pattern layout for the device, showing a silk-based scaffold design.
  • item A is a hexagonal or diamond shaped pore device each with a square area of about 4 square millimeters, other shape configuration may be designed such as round or polygonal as well as a different square area value.
  • This device is preferably created on a raschel knitting machine such as Comez DNB/EL-800-8B-P set up in 10 gg needle spacing by the use of four movements as shown by the pattern layout in FIG. 7 and Fig. 8 and FIG. 9 with two movements in the wale direction, the vertical direction within the fabric, and two movements in the course direction, the horizontal direction of the fabric.
  • the movements in the wale direction occur on separate needle beds with alternate yarns; loops that occur on every course are staggered within repeat. While being knit the yarn follows a repeat pattern of 3/1 -1/1 -1/3-3/3 for one of the wale direction movements and 1/1 -1/3-3/3-3/1 for the other wale direction movement, with each number representing a position, each 7" representing a guide bar movement, and each "-" representing a course (or stitch). For example, a yarn following a pattern of 3/1 - 1/1 -1/3-3/3 would start in position 3 (located between the second and third needle slots) and move, as indicated by the 7", to position 1 .
  • the knitting needles would form a stitch (as indicated by the "-"), remain in position 1 (since 1/1 represents no movement), form another stitch, move from position 1 to position 3, form another stitch, and then remain in position 3 (since 3/3 would also represent no movement).
  • the pattern would repeat for the full length of the fabric. The same notation method can be applied to all stitch patterns and on all guide bars listed.
  • the pattern adopts a yarn design made with 3 ends of Td 20/22 raw silk twisted together in the S direction to form a ply with 20 tpi and further combining 3 of the resulting ply with 10 tpi in the Z direction.
  • the same yarn design is used for the movements occurring in the wale and course directions.
  • the stitch density or pick count for the scaffold design is preferably 40 picks per centimeter including the total picks count for the technical front face and the technical back face of the fabric, or equivalently 20 picks per cm considering only one face of the fabric.
  • the operating parameters are not limited to those described but just the optimum values for the physical properties of the device as a mesh or scaffold with the knit structure set forth which includes a twisted yarn. Sericin is preferably removed from the silk fibroin fibers after the yarn is formed (that is after the silk fibroin fibers have been twisted together, but not yet knitted) but before the mesh has been knit and/or after the device has been knitted.
  • a preferred embodiment of the device is made of a 9 filament, twisted, and purified (sericin depleted) silk fiber.
  • the yarn is then warp knitted as set forth above to thereby make the device.
  • the properties of the device include improved drapability, stretch, and conformability as compared to SERI standard 102 (SERI Surgical Scaffold), as shown in Table 5 below, where "SERI Standard 102" is the known SERI® Surgical Scaffold, and "SERI Pliable Sterilized” is the present device.
  • Table 5 properties were achieved, in part, by creating a symmetrical, diamond shaped pore that allows for bidirectional stretch. Selected further physical properties of an embodiment of the device are shown by Table 6.
  • N/mm means Newton per millimeter
  • N N
  • mg/mm means milligram per millimeter.
  • the pliable silk device of Example 1 (“the device”) can be used as a transitory scaffold for soft tissue support and repair in two-stage breast reconstruction to reinforce deficiencies where weakness or voids existed that required the addition of material to obtain the desired surgical outcome.
  • the device is supplied sterile in a with one device utilized per breast.
  • the device placed during each subject's stage I breast reconstruction with a tissue expander placement procedure. Following mastectomy (either immediate or delayed), the surgical site is readied for subpectoral tissue expander insertion in accordance with standard surgical methods.
  • the tissue expander is rinsed in antibiotic solution (according to standard of care) and inserted into the subpectoral pocket.
  • the device s cut to size (prior to, during, and/or after suturing) to repair the void between the pectoral muscle and the chest wall (i.e., inframammary fold region).
  • the device is rinsed with antibiotic solution and sutured in place, with a minimum suture bite of 3 mm or one full row of material. If any cutting is performed in situ, rinsing of the implant site is performed. Intra-operative photography is taken of the device prior to closure.
  • the tissue expander is filled as appropriate, drains placed according to usual standard of care and number and location of drain(s) noted. Standard rinsing of the surgical site and closure is performed. Prophylactic antibiotic use and duration is documented.
  • tissue expander is removed and replaced with a breast implant.
  • the surgical approach used to remove the tissue expander Implant placement is subpectoralis muscle and the pocket is prepared.
  • the breast implant is rinsed in antibiotic solution and positioned within the pocket. Closure is performed.
  • the device provides soft tissue support and facilitates positioning of the implanted tissue expander.
  • the stage I implanted expander is a temporary implant.
  • the stage II breast implant is intended to be a permanent implant, typically remaining implanted in the patient for ten or more years.
  • the device also provides stabilization of the pectoralis muscle and can as well assist with maintenance of the position and appearance of the inframammary fold during stage I of a breast reconstruction and can provide this function after stage I as well.
  • stage II when the tissue expander is removed and the breast implant is implanted
  • the device is then fully or at least partially integrated within the underlying soft tissue which has grown into and around the pores of the scaffold.
  • the device begins to be bioresorbed as soon as the device had been implanted in a patient and the device is completely bioresorbed after about one to four years after implantation.
  • the device is implanted at stage I to help hold the tissue expander in place (the device is sutured in to form a pocket in which the tissue expander rests and/or the device is draped over the tissue expander).
  • stage II when the tissue expander is removed and replaced by a breast implant (saline or gel filled) the device is not removed and the device remains in place within the patient.
  • no additional or further device is implanted in the patient at stage II or thereafter.
  • the device implanted in the patient in stage I provides soft tissue support and along with the implanted tissue expander maintains the existence of a pocket or space during stage I (the tissue expansion stage) that is until the stage II breast implant implantation in the patient into the pocket or space so maintained during stage I.
  • the device assists to ensure that a pocket or space is available for the placement of the stage II breast implant.
  • the stage I implanted device is left in place implanted in the patient and is not removed. By stage II the device has be incorporated into the underlying soft tissue and vasculature has grown in and around it.
  • the scaffold is comprised entirely of or consists essentially of sericin depleted, knitted silkworm silk.
  • the implanted device begins to be biodegraded or bioresorbed as soon as it is implanted in a patient.
  • the fabric is completely (100%) bioresorbed (biodegraded) within about one year to about four years after implantation in a patient.
  • Example 1 The device of Example 1 is supplied sterile in a single-use size with one device utilized per breast.
  • the device is implanted in the subject immediately post mastectomy, during the breast implant placement surgery, in a direct-to-implant breast reconstruction procedure.
  • the device is used in in DTI breast reconstruction is used.
  • the surgical site is readied for subpectoral breast implant insertion in accordance with standard surgical methods.
  • the breast implant is rinsed in antibiotic solution and inserted into the subpectoral pocket.
  • the device is optionally cut to size (prior to, during, and/or after suturing) to repair the void between the pectoral muscle and the chest wall (i.e., inframammary fold region).
  • the device is rinsed with antibiotic solution and sutured in place to both the pectoralis muscle and chest wall, with a minimum suture bite of 3 mm or one full row of material. If any cutting was performed in situ, rinsing of the implant site is performed. Drains are placed according to usual standard of care and number and location of drain(s) noted.
  • the device can be used as a transitory scaffold for soft tissue support and repair to reinforce deficiencies where weakness or voids exist that require the addition of material to obtain the desired surgical outcome, including but not limited to reinforcement of soft tissues in reconstructive and plastic surgery to obtain the desired aesthetic outcome.
  • the device should not be used in patients with a known allergy to silk nor in direct contact with bowel or viscera where formation of adhesions may occur. To use the device:
  • the device is stored in its original sealed package away from direct sources of heat at ambient room temperature.
  • sutures should be placed at least 3mnn, or one full row, from the cut edge of the device .
  • the uncut device can be sutured over the patient defect and trimmed once secured in place followed by rinsing and aspiration.
  • the device should be sufficiently anchored to stabilize it during tissue ingrowth.
  • the device should be rolled along its long axis and may be delivered through a 7/8mm or larger cannula.
  • hernia repair is a traditional hernia repair procedure.
  • approaches for performing this type of hernia repair are performed routinely with local and intravenous sedation. Due to the larger size of the incision, open hernia repair is generally painful with a relatively long recovery period.
  • Minimally invasive (laparoscopic) repair is usually performed under general anesthesia. Spinal anesthesia and local anesthesia are used under certain circumstances. Benefits associated with minimally invasive (laparoscopic) repair include shorter operative time, less pain, and a shorter recovery period.
  • ventral hernia repair Another form of laparoscopic hernia repair is ventral hernia repair (laparoscopic).
  • Incisional, ventral, epigastric, or umbilical hernias are defects of the anterior abdominal wall and may be congenital (umbilical hernia) or acquired (incisional).
  • Incisional hernias form after surgery through the incision site or previous drain sites, or laparoscopic trocar insertion sites. Incisional hernias often occur after open surgical procedures. These hernias present with a bulge near or at a previous incision.
  • the device (a prosthetic mesh) is used in order to minimize tension on the repair so as to reduce the chance of hernia recurrence.
  • an old incision scar is incised and removed. Inspection of the entire length of the incision generally uncovers multiple hernia defects. The area requiring coverage is usually large and requires much surgical dissection.
  • the device is used to cover the defect before closure of the wound. This is a major and often complex surgical procedure. The use of the device decreases possible recurrence. A patient typically returns to normal activity within a matter of weeks.
  • the principles governing a laparoscopic ventral hernia repair are based on those of open Stoppa ventral hernia repair.
  • a large piece of the device is placed under the hernia defect with a wide margin of mesh outside the defect, and the mesh is anchored in to place and secured to the anterior abdominal wall. The device is anchored into place, for example, by sutures.
  • the device is secured to the anterior abdominal wall, for example, by tacks which are placed laparoscopically.
  • the device can be used in body aesthetics and body contouring surgical procedures.
  • One such embodiment relates to use of the device in abdominoplasty.
  • the time needed for conducting an abdominoplasty also varies depending upon the type of abdominoplasty to be performed. For example, a complete abdominoplasty typically is completed in 1 to 5 hours.
  • a partial abdominoplasty, also referred to as a mini-tuck abdominoplasty is typically completed in 1 to 2 hours.
  • reconstruction of the umbilicus commonly referred to as the belly button, may also occur.
  • the original umbilicus is attached, such as by sutures, into a new hole created by the surgeon.
  • a complete abdominoplasty is also referred to as a full abdominoplasty.
  • a complete abdominoplasty an incision is made from hip to hip just above the pubic area. Another incision is made to separate the navel from the surrounding skin. The skin is detached from the abdominal wall to reveal the muscles and fascia to be tightened. The muscle fascia wall is tightened with sutures. The remaining skin and fat are tightened by removing the excess and closing. The old belly button stalk is brought out through a new hole and sutured into place. Liposuction may also be used to refine the transition zones of the abdominal contouring. A surgical dressing and optionally a compression garment are applied. Excess fluid from the site is drained.
  • a complete abdominoplasty may also comprise a musculofascial plication abdominal dermal lipectomy and/or suction-assisted lipectomy of hips.
  • a partial abdominoplasty is also referred to as a mini abdominoplasty.
  • a partial abdominoplasty a smaller incision is made as compared to a complete abdominoplasty.
  • the skin and fat of the lower abdomen are detached in a more limited manner from the muscle fascia.
  • the skin is stretched down and excess skin removed.
  • the belly button stalk may be divided from the muscle below and the belly button slid down lower on the abdominal wall.
  • a portion of the abdominal muscle fascia wall is optionally tightened. Liposuction is often used to contour or sculpt the transition zone. The flap is stitched back into place. A combination abdominoplasty and liposuction procedure is often referred to as a "lipo-tuck". During such procedure, skin is removed and subsequently sutured. As noted above, the belly button is reattached to a new hole created by the surgeon.
  • An extended abdominoplasty is a complete abdominoplasty plus a lateral thigh lift.
  • the patient is cut from the posterior axillary line.
  • the operation includes all of the abdominal contouring of a complete abdominoplasty plus allows further improvement of the flank (waist), as well as smoothing the contour of the upper lateral thigh.
  • a high lateral tension tummy tuck is a more involved procedure and typically takes at least four and half hours to perform.
  • muscles are also tightened horizontally. The procedure provides a patient with a flat abdomen and with an improved waistline.
  • a circumferential abdominoplasty also referred to as a belt lipectomy or body lift, is an extended abdominoplasty in conjunction with a buttock lift.
  • the incision typically runs all the way around the body. This surgical procedure is suitable, for example, for patients who have undergone massive weight loss.
  • abdominoplasty may be conducted in the course of a lower body lift.
  • abdominoplasty is combinable with liposuction contouring, breast reduction, breast lift, or a hysterectomy.
  • Breast enhancement procedures performed in conjunction with an abdominoplasty are often referred to as a "mommy makeover".
  • barbed sutures may be employed.
  • An abdominoplasty procedure can be conducted using the device
  • the typical fascial is done first, using a row of figure of eight sutures, first and then another layer of running suture all #1 PDS (polydioxanone suture, Ethicon)
  • Two pieces of the device can be used as an onlay to augment the fascia tightening.
  • One 10 x 25 cm piece can be used in the lower abdomen. It can be laced transversely, the vertical dimension 10 cm, can be positioned with the lower edge at level of the pubic symphsis, and the upper edge at the lower border of the umbilicus.
  • the 25 cm transverse dimension can be suitable.
  • a second scaffold can be cut and tailored to use in the supra-umbilcal region, with care taken not to leave too close to the umbilical closure. As the closure around the umbilicus occasionally may not heal primarily, extra care is taken with sutures/device in this location.
  • the handling characteristics can be excellent.
  • the device is secured at its periphery with a 3-0 V-Lock (COVIDIEN brand of barbed suture, made of a material similar to PDS).
  • COVIDIEN brand of barbed suture made of a material similar to PDS.
  • the patient can do very well and can be hospitalized overnight. The patient has a total of 5, ten mm flat blake drains - two that drain the back and three in the front. The patient stays on antibiotics until drains were which is typically within 10 to 20 days.
  • a device is a biocompatible, bioresorbable, pliable surgical matrix (mesh or scaffold) made preferably from the silk of the Bombyx mori silkworm. Because raw silk fibers are comprised of a fibroin protein core filament that is naturally coated with the antigenic globular protein sericin the sericin is removed by aqueous extraction. Yarn is then made from the sericin-depleted fibroin protein filaments by helical twisting to form a multi-filament protein fiber. The multi-filament protein fiber yarn is then knit into a three dimensional patterned matrix (mesh or scaffold) that can be used for soft tissue support and repair.
  • a biocompatible, bioresorbable, pliable surgical matrix made preferably from the silk of the Bombyx mori silkworm. Because raw silk fibers are comprised of a fibroin protein core filament that is naturally coated with the antigenic globular protein sericin the sericin is removed by aqueous extraction. Yarn is then made from the sericin-de
  • the device upon implantation provides immediate physical and mechanical stabilization of tissue defects because of its strength and porous construction. Additionally, the porous lattice design of the device facilitate native tissue generation (that is tissue ingrowth) and neovascularization.
  • the natural tissue repair process begins with deposition of a collagen network. This network integrates within the protein matrix, interweaving with the porous construct.
  • Neovascularization begins with endothelial cell migration and blood vessel formation in the developing functional tissue network. This new functional tissue network and its corresponding vascular bed ensure the structural integrity and strength of the tissue.
  • the device provides the majority of structural support.
  • the device (made of silk) is gradually deconstructed (bioresorbed) into its amino acid building blocks. The slow progression of the natural biological process of bioresorption allows for the gradual transition of support from the protein matrix of the device to the healthy native tissue thereby achieving the desired surgical outcome.

Landscapes

  • Engineering & Computer Science (AREA)
  • Textile Engineering (AREA)
  • Knitting Of Fabric (AREA)

Abstract

Une maille de soie tricotée pliable, implantable à utiliser dans le support et la réparation de tissu mou humain a un motif de tricot spécifique qui empêche sensiblement l'effilochage et préserve la stabilité de la maille lors de sa coupe, la maille tricotée comprenant au moins deux fils posés dans une direction de tricotage et s'imbriquant l'un dans l'autre pour former une pluralité de noeuds.
PCT/US2015/045716 2014-08-18 2015-08-18 Dispositif médical en soie pliable WO2016028797A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/462,473 US9308070B2 (en) 2008-12-15 2014-08-18 Pliable silk medical device
US14/462,473 2014-08-18

Publications (1)

Publication Number Publication Date
WO2016028797A1 true WO2016028797A1 (fr) 2016-02-25

Family

ID=54035304

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/045716 WO2016028797A1 (fr) 2014-08-18 2015-08-18 Dispositif médical en soie pliable

Country Status (1)

Country Link
WO (1) WO2016028797A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9806818B2 (en) 2015-07-23 2017-10-31 At&T Intellectual Property I, Lp Node device, repeater and methods for use therewith

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5245012A (en) 1990-04-19 1993-09-14 The United States Of America As Represented By The Secretary Of The Army Method to achieve solubilization of spider silk proteins
WO1997008315A1 (fr) 1995-08-22 1997-03-06 Basel Richard M Procedes de clonage servant a obtenir des proteines de soie d'araignee extremement resistantes
US20120150204A1 (en) * 2008-12-15 2012-06-14 Allergan, Inc. Implantable silk prosthetic device and uses thereof
US20130317526A1 (en) * 2008-12-15 2013-11-28 Allergan, Inc. Silk medical device
WO2015027144A1 (fr) * 2013-08-22 2015-02-26 Allergan, Inc. Dispositifs médicaux implantables

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5245012A (en) 1990-04-19 1993-09-14 The United States Of America As Represented By The Secretary Of The Army Method to achieve solubilization of spider silk proteins
WO1997008315A1 (fr) 1995-08-22 1997-03-06 Basel Richard M Procedes de clonage servant a obtenir des proteines de soie d'araignee extremement resistantes
US20120150204A1 (en) * 2008-12-15 2012-06-14 Allergan, Inc. Implantable silk prosthetic device and uses thereof
US20130317526A1 (en) * 2008-12-15 2013-11-28 Allergan, Inc. Silk medical device
WO2015027144A1 (fr) * 2013-08-22 2015-02-26 Allergan, Inc. Dispositifs médicaux implantables

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALTMAN ET AL.: "Silk matrix for tissue engineered anterior cruciate ligaments", BIOMATERIALS, vol. 23, 2002, pages 4131 - 4141
GREGORY H. ALTMAN ET AL.: "Silk matrix for tissue engineered anterior cruciate ligaments", BIOMATERIALS, vol. 23, 2002, pages 4131 - 4141

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9806818B2 (en) 2015-07-23 2017-10-31 At&T Intellectual Property I, Lp Node device, repeater and methods for use therewith

Similar Documents

Publication Publication Date Title
US9308070B2 (en) Pliable silk medical device
US9204953B2 (en) Biocompatible surgical scaffold with varying stretch
US9326840B2 (en) Prosthetic device and method of manufacturing the same
US20170258573A1 (en) Silk medical device for use in breast augmentation and breast reconstruction
US20140277000A1 (en) Implantable silk prosthetic device and uses thereof
US20120004723A1 (en) Prosthetic device and method of using in breast augmentation and/or breast reconstruction
US20160213456A1 (en) Silk medical device
US20120185041A1 (en) Silk medical device for use in breast augmentation and breast reconstruction
US20120022646A1 (en) Prosthetic device and method of using in breast augmentation and/or breast reconstruction
US20140088700A1 (en) Method for using a silk derived bioresorbable scaffold in breast reconstruction
US10648109B2 (en) Pliable silk medical device
CA2900682A1 (fr) Dispositif medical en soie destine a etre utilise en augmentation mammaire et en reconstruction mammaire
US20130253646A1 (en) Silk based implantable medical devices and methods for determining suitability for use in humans
US20130245757A1 (en) Method and device for improved soft tissue surgery
US20130116785A1 (en) Silk based implantable medical devices and methods for determining suitability for use in humans
WO2016028797A1 (fr) Dispositif médical en soie pliable
WO2014093837A1 (fr) Dispositif médical de soie
CA2854573A1 (fr) Maille de soie et ses procedes d'utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15757375

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15757375

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载